Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XPACE-2005
- Development stage
- Preclinical
- Lead developer
- Xanadu Bio
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal, Inhalation
01
Overview
XPACE-2005 is a trivalent mRNA vaccine candidate developed by Xanadu Bio, designed to provide simultaneous protection against COVID-19, influenza, and respiratory syncytial virus (RSV). Utilizing the proprietary PACE (Polymer for Advancement of Cell Engineering) platform, the vaccine employs polymer nanoparticles to deliver mRNA encoding the SARS-CoV-2 spike protein, influenza hemagglutinin (HA), and an RSV antigen directly to the airway epithelium. This mucosal delivery approach, intended for intranasal or inhaled administration, is designed to induce local immunity at the primary site of viral entry, potentially offering enhanced protection against infection and transmission compared to traditional systemic vaccines. As of early 2025, the program is in the lead optimization stage of preclinical development.
- Other names
- XPACE-2005 Spike/HA/RSV vaccine
02
Targets
HA (Hemagglutinin)RSV G (Respiratory syncytial virus attachment glycoprotein)SARS-CoV-2 spike
Beyond the preview
Go deeper on XPACE-2005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XPACE-2005.